Worldwide Dermatology Drugs Industry to 2030 – Featuring Allergan, Galderma and Novartis Among Others – ResearchAndMarkets.com

Worldwide Dermatology Drugs Industry to 2030 – Featuring Allergan, Galderma and Novartis Among Others – ResearchAndMarkets.com




Worldwide Dermatology Drugs Industry to 2030 – Featuring Allergan, Galderma and Novartis Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dermatology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs market as it emerges from the COVID-19 shut down.

The global dermatology drugs market is expected to grow from $37.57 billion in 2020 to $40.49 billion in 2021 at a compound annual growth rate (CAGR) of 7.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $62.83 billion in 2025 at a CAGR of 12%.

Companies Mentioned

  • Johnson & Johnson
  • Allergan Plc
  • Galderma S.A
  • Novartis AG
  • GlaxoSmithKline Plc

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Asia Pacific was the largest region in the global dermatology drugs market, accounting for 36% of the market in 2020. North America was the second largest region accounting for 27% of the global dermatology drugs market. Africa was the smallest region in the global dermatology drugs market.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers.

The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP grew from $11 trillion in 2015 to $13.6 trillion in 2018. Additionally, according to the World Economic Outlook Reports by the IMF, emerging markets and developing economies together registered a growth of 4.0% in 2015 and this increased to 4.5% in 2018. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Dermatology Drugs Market Characteristics

4. Dermatology Drugs Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Dermatology Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Dermatology Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Dermatology Drugs Market Trends and Strategies

8. Impact of COVID-19 on Dermatology Drugs

9. Dermatology Drugs Market Size and Growth

9.1. Market Size

9.2. Historic Market Growth, Value ($ Billion)

9.2.1. Drivers of the Market

9.2.2. Restraints on the Market

9.3. Forecast Market Growth, Value ($ Billion)

9.3.1. Drivers of the Market

9.3.2. Restraints on the Market

10. Dermatology Drugs Market Regional Analysis

10.1. Global Dermatology Drugs Market, 2020, by Region, Value ($ Billion)

10.2. Global Dermatology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region

10.3. Global Dermatology Drugs Market, Growth and Market Share Comparison, by Region

11. Dermatology Drugs Market Segmentation

11.1. Global Dermatology Drugs Market, Segmentation by Type

11.2. Global Dermatology Drugs Market, Segmentation by Distribution Channel

11.3. Global Dermatology Drugs Market, Segmentation by Route of Administration

11.4. Global Dermatology Drugs Market, Segmentation by Drug Classification

11.5. Global Dermatology Drugs Market, Segmentation by Mode of Purchase

12. Dermatology Drugs Market Metrics

12.1. Dermatology Drugs Market Size, Percentage of GDP, 2015-2025, Global

12.2. Per Capita Average Dermatology Drugs Market Expenditure, 2015-2025, Global

For more information about this report visit https://www.researchandmarkets.com/r/aslcb6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900